Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?

被引:13
|
作者
Arias-Carrion, Oscar [1 ]
Machado, Sergio [2 ,3 ,4 ,5 ]
Paes, Flavia [2 ,3 ,6 ]
Velasques, Bruna [4 ,5 ]
Teixeira, Silmar [5 ]
Cardenas-Morales, Lizbeth [7 ]
Piedade, Roberto [5 ]
Ribeiro, Pedro [4 ,5 ,8 ]
Nardi, Antonio E. [2 ,3 ]
机构
[1] Univ Marburg, Dept Neurol, D-35033 Marburg, Germany
[2] Univ Fed Rio de Janeiro, Pan & Respirat Lab, Inst Psychiat, Rio De Janeiro, Brazil
[3] Natl Inst Translat Med INCT TM, Rio De Janeiro, Brazil
[4] Inst Appl Neurosci INA, Rio De Janeiro, Brazil
[5] Univ Fed Rio de Janeiro, IPUB UFRJ, Inst Psychiat, BR-21941 Rio De Janeiro, Brazil
[6] Brazilian Inst Med & Rehabil IBMR, Fac Psychol, Rio De Janeiro, Brazil
[7] Univ Ulm, Dept Psychiat, D-89069 Ulm, Germany
[8] Biosci Dept EEFD UFRJ, Sch Phys Educ, Rio De Janeiro, Brazil
关键词
rTMS; Parkinson's disease; cellular and molecular mechanisms; neurorehabilitation; sensorimotor integration; TRANSCRANIAL-MAGNETIC-STIMULATION; HUMAN MOTOR CORTEX; NONINVASIVE BRAIN-STIMULATION; LEVODOPA-INDUCED DYSKINESIAS; SINGLE-UNIT ACTIVITY; PREFRONTAL CORTEX; RAT-BRAIN; DOPAMINE RELEASE; HIGH-FREQUENCY; VISUAL-CORTEX;
D O I
10.2174/187152711797247821
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive procedure whereby a pulsed magnetic field stimulates electrical activity in the brain. Parkinson's disease (PD) is a neurodegenerative process characterized by numerous motor and nonmotor clinical manifestations for which effective, mechanism-based treatments remain elusive. Consequently, more advanced non-invasive therapeutic methods are required. A possible method of rehabilitation that may be effective and potentially viable for use in clinical practice is rTMS. Here, we focus on the basic foundation of rTMS, the main findings of rTMS from animal models, the effects of rTMS on sensorimotor integration in patients with PD, and the experimental advances of rTMS that may become a viable clinical application to treat the disease.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 50 条
  • [11] Immunotherapy for Parkinson's disease: a developing therapeutic strategy
    Bradbury, J
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (16) : 1075 - 1076
  • [12] Targeting α-synuclein as a therapeutic strategy for Parkinson's disease
    Lawand, Nada B.
    Saade, Nayef E.
    El-Agnaf, Omar M.
    Safieh-Garabedian, Bared
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (10) : 1351 - 1360
  • [14] The features and management of poisoning with drugs used to treat Parkinson's disease
    Jones, AL
    Proudfoot, AT
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1997, 90 (10) : 613 - 616
  • [15] Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease
    Yang, Yunseon
    Song, Jae-Jin
    Choi, Yu Ree
    Kim, Seong-Hoon
    Seok, Min-Jong
    Wulansari, Noviana
    Darsono, Wahyu Handoko Wibowo
    Kwon, Oh-Chan
    Chang, Mi-Yoon
    Park, Sang Myun
    Lee, Sang-Hun
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (29)
  • [16] RNA knockdown as a potential therapeutic strategy in Parkinson's disease
    Manfredsson, FP
    Lewin, AS
    Mandel, RJ
    [J]. GENE THERAPY, 2006, 13 (06) : 517 - 524
  • [17] Gene therapy: a viable therapeutic strategy for Parkinson’s disease?
    Alexander L. Berry
    Thomas Foltynie
    [J]. Journal of Neurology, 2011, 258 : 179 - 188
  • [18] Comment on: “Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease”
    Juan Segura-Aguilar
    [J]. CNS Drugs, 2018, 32 : 685 - 686
  • [19] Gene therapy: a viable therapeutic strategy for Parkinson's disease?
    Berry, Alexander L.
    Foltynie, Thomas
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 (02) : 179 - 188
  • [20] Glia as a Turning Point in the Therapeutic Strategy of Parkinson's Disease
    L'Episcopo, Francesca
    Tirolo, Cataldo
    Testa, Nuccio
    Caniglia, Salvo
    Morale, Maria Concetta
    Marchetti, Bianca
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (03) : 349 - 372